We are live on ! Find out more
MPLT

MapLight Therapeutics

81 hedge funds and large institutions have $502M invested in MapLight Therapeutics in 2026 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 26 increasing their positions, 13 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 13

57% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 14

24% more capital invested

Capital invested by funds: $405M → $502M (+$97M)

13% more funds holding in top 10

Funds holding in top 10: 89 (+1)

9% more funds holding

Funds holding: 7481 (+7)

7.37% more ownership

Funds ownership: 50.84%58.21% (+7.4%)

Holders
81
Holders Change
+7
Holders Change %
+9.46%
% of All Funds
1%
Holding in Top 10
9
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+12.5%
% of All Funds
0.11%
New
22
Increased
26
Reduced
13
Closed
14
Calls
Puts
Net Calls
Net Calls Change

MPLT Hedge Fund Activity: Q1 2026 in Review

81 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in MapLight Therapeutics (MPLT) for Q1 2026, worth a combined $502M — up 24% from $405M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new MPLT positions and 14 closed out — a net gain of 8 holders — while 26 added to existing stakes and 13 trimmed.

The largest buyer was Blue Owl Capital Holdings, adding an estimated $12.1M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $9.66M sold.

  • 81 institutional investors held MapLight Therapeutics (MPLT) as of Q1 2026, up from 74 in Q4 2025.
  • Funds reported $502M of MapLight Therapeutics stock for Q1 2026, up 24% quarter-over-quarter.
  • 22 funds opened new MapLight Therapeutics positions in Q1 2026 and 14 closed out, a net change of +8 holders.
  • The largest MapLight Therapeutics buyer in Q1 2026 was Blue Owl Capital Holdings, an estimated $12.1M added.
  • The largest MapLight Therapeutics seller in Q1 2026 was Perceptive Advisors, an estimated $9.66M sold.

Based on aggregated 13F filings for Q1 2026.